Adherence and Persistence with Glaucoma Therapy
Section snippets
Adherence
Assessing adherence accurately poses a significant challenge. The methodology used to measure adherence has typically followed one of three techniques: patient self-report, electronic monitoring, or pharmacy refill data assessed by an index called Medication Possession Ratio (MPR). Patient self-report, although simple and inexpensive, tends to overestimate adherence, whether assessed by self-administered questionnaire or interview by trained personnel,22, 31 and it is subject to both recall
Persistence
Persistence with glaucoma medication has been found to be low in several studies (Table 2), varying from 20%47 to 64%.7 Glaucoma suspects beginning latanoprost or a beta-blocker drop had persistency rates of 39% and 25%, retrospectively, at 1 year.44 Another study of patients who began one of seven ocular hypotensive therapies found rates of persistence at 1 year of 33% for the prostaglandin group compared to 19% for the six other classes.38 In a study of 2,850 patients prescribed an ocular
Variability by Drug Class
Several studies have found differences in adherence and persistence by class of ocular hypotensive medication. Separating adverse events/tolerability from frequency of dosing cannot be conclusively determined from retrospective pharmacy claims analyses in the absence of chart review or patient interview. Cost may also play a role; however, the majority of studies evaluating class differences were performed in a setting of pharmacy benefit coverage. Prostaglandins have been found to have higher
Clinical Implications and Techniques for Improving Adherence and Persistence
Determining, maintaining, and adjusting a target pressure range for patients are important parts of glaucoma care. A patient who resumes medication shortly before an office visit after a gap in therapy may appear to be at an optimal pressure, yet visual field progression may have occurred. It becomes impossible to sort out if the pressure goal needs to be further lowered, typically requiring additional therapy, or if the pressure goal is appropriate, but the patient is progressing because of
Summary
Medications only work for patients who take them.5 Glaucoma patients may have variable clinical courses based on the disease itself, but this is further confounded by improper or irregular medication use. Greater awareness by the physician of the widespread nature of nonadherence is a very important component of patient care. Tracking of patients who fail to follow-up is crucial; this can be improved with the use of telephone reminder calls for appointments.13 Discussion with patients should
Method of Literature Search
Database used: www.pubmed.com. Years searched:1970–present. Search terms: compliance, persistence, adherence, glaucoma, glaucoma medication. Additionally used references cited in the reference lists of other articles. Busche and Gramer3 is the only non-English reference used, for which the English translation was used.
References (54)
- et al.
A systematic review of the associations between dose regimens and medication compliance
Clin Ther
(2001) - et al.
Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension
Clin Ther
(2006) - et al.
The TRAVATAN Dosing Aid accurately records when drops are taken
Am J Ophthalmol
(2007) - et al.
Glaucoma management among individuals enrolled in a single comprehensive insurance plan
Ophthalmology
(2005) - et al.
Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy?
Am J Ophthalmol
(1986) - et al.
Compliance with topical timolol treatment
Am J Ophthalmol
(1987) - et al.
Compliance with topical pilocarpine treatment
Am J Ophthalmol
(1986) - et al.
Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic
Ophthalmology
(1998) - et al.
Reliability of blood glucose monitoring by patients with diabetes mellitus
Am J Med
(1984) Monitoring compliance with pilocarpine therapy
Am J Ophthalmol
(1981)
Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study
Ophthalmology
Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study
Clin Ther
Patient persistency with topical ocular hypotensive therapy in a managed care population
Am J Ophthalmol
Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?
Ophthalmology
Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma
Clin Ther
Accounting for restart rates in evaluating persistence with ocular hypotensives
Ophthalmology
Persistency with latanoprost or timolol in primary open-angle glaucoma suspects
Am J Ophthalmol
Patient-reported behavior and problems in using glaucoma medications
Ophthalmology
Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head
Am J Ophthalmol
Determination of acetazolamide compliance in patients with glaucoma
Arch Ophthamol
Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France
Eur J Ophthalmol
[Improved eyedrop administration and compliance in glaucoma patients. A clinical study]
Klin Monatsbl Augenheilkd
Effect of partial compliance on cardiovascular medication effectiveness
Heart
Accuracy and performance of a commercially available Dosing Aid
Br J Ophthalmol
Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data
Am J Manag Care
Chronic open angle glaucoma: patient awareness of the nature of the disease, topical medication, compliance and the prevalence of systemic symptoms
Ophthalmic Physiol Opt
Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study
Eur J Ophthalmol
Cited by (0)
The supplement in which this article is published was funded by Pfizer. Dr Schwartz serves as a consultant to Pfizer and has received research grants from Pfizer and Allergan. Dr Quigley serves as a consultant to Pfizer, Allergan, and Alcon. The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.